A Phase 2 interventional study of Treatment De-escalation and Additional Treatment in Co-existent Endometrial and Ovarian Carcinoma, Ovarian Carcinoma and Endometrial Carcinoma (EC), sponsored by British Columbia Cancer Agency. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by British Columbia Cancer Agency · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 273 studies in Ovarian Neoplasms with a site in Canada — 49 open to participants now, 89 under way, 27 of them phase 3. Ovarian Neoplasms · Canada.
Among the 273 studies in Ovarian Neoplasms with a site in Canada, this one is the 148th largest by planned enrollment of the 239 interventional ones that give a count, is one of 12 that started in 2026, is one of 90 in phase 2, reaches primary completion later than 85 of the 88 other live ones, and was the 272nd registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →49 of the 273 studies in Ovarian Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Canada, Argentina, Australia and 2 more countries
Ages 18+ · Women only
AstraZeneca · Sites in Canada, United States, Australia and 10 more countries
Ages 18+ · Women only
GlaxoSmithKline · Sites in Canada, Australia, Japan and 1 more country
Ages 18+ · Women only
AbbVie · Sites in Canada, Argentina, Brazil and 2 more countries
Ages 18+ · Women only
GlaxoSmithKline · Sites in Canada, Australia, Japan and 2 more countries
Ages 18+ · Women only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
273 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 119 · Phase 3 65 · Phase 4 2
First in 1991; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 136 across the 239 interventional studies, 190 across the 19 observational. Of the 174 that completed or were terminated, 63 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 273 have an industry lead sponsor. The 10 most frequent:
British Columbia Cancer Agency is the lead sponsor of 153 studies on the registry; 34 are open to participants now.
British Columbia Cancer Agency has 7 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
27 of the studies in Ovarian Neoplasms with a site in Canada that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT04095364Phase 3NRG OncologyLetrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | 2027-02-01 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
Add all 27 to your calendar (.ics) → With an account.
Among the 273 studies in Ovarian Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with co-existent endometrial and ovarian carcinomas (CEOCs) are treated inconsistently due to a lack of clear standardized treatment guidelines. Patients may be over-treated and face substantial physical side effects and financial challenges due to additional chemotherapy or radiation appointments. Previous retrospective research has shown that using specific molecular and pathologic criteria to stratify patients' CEOC tumours can identify patients at very low risk of cancer recurrence (during an average 6 years of follow-up), with no demonstrated benefit of additional treatment after surgery.
The goal of this study is to determine the safety of receiving no additional treatment (i.e. no chemotherapy or radiation) after surgery in patients diagnosed with a co-existent endometrial and ovarian cancer (CEOC) meeting highly selective molecular and pathologic criteria. Patients with CEOC who also meet predefined molecular criteria (low risk POLEmut, ER+NSMP, or MSH2/MSH6/PMS2 loss without MLH1 promoter hypermethylation in the endometrium and ovary) and pathology criteria (see schema) are eligible to participate. Patients may choose, or be directed by their physician to receive no additional treatment after surgery or to receive additional treatment.
To determine the safety of this approach, the study team will evaluate pelvic recurrence (primary) rate, as well as vaginal and distant recurrences, recurrence-free and disease- specific, and overall survival, quality of life, and health economic metrics among patients who do, and do not receive additional treatment after surgery.
Study design is pragmatic, designed to match recommended standard of care as closely as possible. Patients will have regular follow-up appointments with their oncologist every 4 months for 3 years as part of their medical care. During this time, patients will complete quality of life surveys at baseline, 4, 12, 24, and 36 months. Baseline imaging, and imaging at completion of 3-years are required.
PURPOSE: To determine the safety of de-escalated/optimized adjuvant treatment of patients with CEOC directed by tumor molecular status and strictly defined pathology criteria.
HYPOTHESIS: Molecular classification in combination with carefully selected and restricted pathological features will identify a subset of patients with CEOCs who are at very low risk of disease recurrence and are candidates for de-escalated/optimized adjuvant therapy.
JUSTIFICATION: CEOC patients are often given chemotherapy +/- pelvic radiation, despite unclear benefit and substantial toxicity from short and long termshort- and long-term treatment-related side effects, such as neuropathy, fatigue and cognitive issues. Overtreatment also results in financial challenges for patients from loss of income, travel expenses related to many appointments and delayed return to work. Although the World Health Organization created a new substage within the endometrial cancer staging system to support the delivery of less (or no) treatment for CEOC patients based on pathology criteria that supports favourable outcomes, studies have shown that molecular features of endometrial cancer can also be used to identify a subset of CEOC patients at very low risk of recurrence who can be directed to treatment de-escalation. In order to further evaluate these findings and change clinical practice, a prospective trial is needed to assess the safety of de-escalated treatment for CEOC patients.
RESEARCH DESIGN: This is a phase II, prospective, multi-centre, trial where pathologic and molecular features will be used to identify patients who can be offered de-escalated therapy. Molecular classification- assessing immunohistochemistry for MMR, p53, and ER status in the endometrium and ovarian tumors will be performed. Next generation sequencing for POLE mutation status is needed at least in the endometrial sample. Molecular criteria to define low risk CEOCs will include POLEmut, ER strong + NSMP, and MSH2/MSH6 or PMS2 loss (MMRd without MLH1 promoter hypermethylation) and provided pathologic criteria are also met would enable patients to be considered for de-escalation. Intermediate and high risk carcinomas, encompassing MLH1 promoter methylated, ER-negative NSMP and p53abn CEOCs would not be enrolled.
The first site will open in BC, Canada. Due to this rare patient population, other high-volume national and international centers will be sought. Collaborating centers will be selected based on access to molecular testing and interest in providing their CEOC patients with the opportunity to participate in this trial.
The aim of this trial is to assess the safety of de-escalated adjuvant treatment in CEOC patients. Patients that fit the eligibility criteria will have the option of choosing to receive treatment de-escalation (no chemotherapy or radiation) vs. additional treatment (chemotherapy +/- radiation) following their primary staging surgery.
Recruitment will take place over 3 years from November 1, 2026 - November 1, 2029. Participants will be followed for 3 years after their enrollment after surgery.
Baseline Measures:
1. EORTC QLQ-30 2. FCRI-SF 3. EQ-5D-5L
These questionnaires will be administered through an online platform for the participant to complete on their own device or on a tablet/laptop provided by the study team. Physical copies will be made available upon patient request.
If patient's do not speak English or feel comfortable completing the questionnaires in English, the study coordinator will attempt to obtain these questionnaires in the patient's preferred language.
Follow-Up Measures:
Recurrence:
If a patient's cancer recurs within the 3 year follow-up period, patients will undergo the following study procedures annually from the date of recurrence:
STATISTICAL ANALYSIS: Assuming 68 patients with molecularly stratified CEOC (exclusion of exclusion of MMRd with MLH1 immunohistochemistry loss or MLH1 promoter hypermethylation, p53abn and NSMP ER negative-low) are accrued over 3 years and followed for 3 years, the total person-years of follow-up would be 306 and the upper 95% confidence limit for the true 3-year pelvic recurrence rate would be 7% when the observed 3-year pelvic recurrence rate is 4% from CEOCs in this cohort. Therefore, a true 3-year pelvic recurrence rate of 7%, which for this trial is considered unacceptably high, can be ruled out with 95% confidence in this cohort. Allowing that \~5% of patients may be lost to follow up and 25% of patients may not elect to undergo de-escalated therapy (e.g., will be treated, not counting towards n=68), we estimate needing to enroll \~90 patients to yield 68 evaluable receiving de-escalation. As the statistical analysis has been designed to demonstrate the safety of de-escalation within the group of patients that received no additional treatment, patients who receive adjuvant treatment following surgery are not part of this trial's statistical analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet the molecular and pathological criteria (1, 2, or 3) as determined or identified by their local oncologist and pathologist:
(Molecular) NSMP ER strong positive:
Endometrial site
Ovarian site
Low grade endometrioid (grade 1-2)
(Molecular) POLEmut
Endometrial site
Ovarian site
Low grade endometrioid (grade 1-2)
(Molecular) MSH2, MSH6, or PMS2 loss (MMRd without MLH1 promoter hypermethylation)
Endometrial site
Ovarian site
Low grade endometrioid (grade 1-2)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After undergoing surgery, patients elect to not receive any further treatment (such as radiation or chemotherapy) to treat their cancer. Instead their condition will be closely followed by their oncologist for 3 years.
Other: Treatment De-escalation
After undergoing surgery, patients elect to receive additional treatment (such as radiation or chemotherapy) to treat their cancer. The type of additional treatment received will be determined by the patient's oncologists in conjunction with the patient. These patients will be closely followed by their oncologist for 3 years.
Other: Additional Treatment
Receiving no further treatment (such as radiation or chemotherapy) after surgery to treat their CEOC.
Also known as: Active surveillance
Receive additional treatment (such as radiation or chemotherapy) after surgery to treat their CEOC.
Also known as: Adjuvant treatment, Additional post-surgical treatment
Pelvic recurrence rate of participants in the treatment de-escalation group
The number of patients who participated in the treatment de-escalation group and developed a recurrence of their cancer in their pelvis within the 3-year follow-up period. Evidence of recurrence may be based on clinical exam, imaging, and/or histologic evidence/biopsy.
Time frame: Enrollment to 3 years
The rate of isolated vaginal recurrence and distant metastases.
The number of patients who participated in the treatment de-escalation group and developed a recurrence of their cancer within their vagina and/or developed distant metastases within the 3-year follow-up period. Evidence of recurrence may be based on clinical exam, imaging, and/or histologic evidence/biopsy.
Time frame: Enrollment to 3 years
Recurrence-free survival (RFS)
Recurrence-free survival is defined as the time from surgery/staging until CEOC disease recurrence. This measure will be obtained through clinical follow-up e.g., symptom review \& physical examinations, performed by the local investigators and the date of recurrence will be recorded by the local study coordinator. This survival measure will be calculated for patients in the treatment de-escalation group and the additional treatment group.
Time frame: Date of surgery to 3 years after study enrollment
Worries about cancer recurrence
The Fear of Cancer Recurrence Inventory - Short Form (FCRI-SF) will be administered to patients to understand their level of worry/fear they have about their cancer recurring over the past month. On the FCRI-SF, a lower score represents little fear or worry of a recurrence whereas a higher score represents greater fear or worry of a recurrence.
Time frame: At enrollment, then at 4, 12, 24, and 36 months after enrollment.
Health economic impact of patients' post-surgery treatment decision
The EuroQol EQ-5D-5L questionnaire will be administered to patients to obtain their health related utility scores to understand the health economic impact of treatment de-escalation compared to receiving additional adjuvant treatment. Patients will indicate their health status on a scale from 0 (worst health status) to 100 (best health status).
Time frame: At enrollment, then at 4, 12, 24, and 36 months after enrollment.
Disease specific survival (DSS)
Disease specific survival is defined as the time from surgery/staging until death from CEOC disease. This measure will be obtained through clinical follow-up e.g., symptom review \& physical examinations, performed by the local investigators and the date of recurrence will be recorded by the local study coordinator. This survival measure will be calculated for patients in the treatment de-escalation group and the additional treatment group.
Time frame: Date of surgery to 3 years after study enrollment
Overall survival (OS)
Overall survival is the time from surgery/staging until death from any cause (including death from CEOC disease or death from other non-cancer related causes). This measure will be obtained through clinical follow-up e.g., symptom review \& physical examinations, performed by the local investigators and the date of recurrence will be recorded by the local study coordinator. This survival measure will be calculated for patients in the treatment de-escalation group and the additional treatment group.
Time frame: Date of surgery to 3 years after study enrollment
Health-related quality of life
The 30-item EORTC QLG Core Questionnaire (EORTC QLQ-C30) will be administered to patients to measure their quality of life throughout the trial. This questionnaire contains different scales to evaluate patients' function, symptoms, and global health status. Raw scores from the questionnaire are converted to a standardized scale from 0 - 100, with a higher score for the function and global health status scales representing a better level of functioning and a higher score for the symptom scale representing a higher level of symptoms experienced.
Time frame: At enrollment, then at 4, 12, 24, and 36 months after enrollment.
Plan to share: Yes — Other researchers can request data from the PI's (McAlpine and Jamieson) directly
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: From study start to 5 years from study completion, estimated.
Start is estimated for Oct 2026; primary completion for Oct 2032, 72 months later.
Of 228 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's planned 72 months is above that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
British Columbia Cancer Agency →